China's manufacturing activity contracted sharply in December for the third month in a row, according to Purchasing Managers' Index (PMI)
The coutry’s PMI came in at 47 points, down from November's 48 and well below the 50-point mark separating growth from contraction, despite China loosening COVID restrictions at the beginning of the month.
For over two years, China had imposed a zero-COVID strategy with strict quarantines, lockdowns, and mass testing that led to unannounced plant closures, disrupted supply chains, and forced permanent company closures.
China abruptly loosened pandemic restrictions on December 7, but the country is still struggling to recover due to a surge in COVID cases.
NBS senior statistician Zhao Qinghe noted that the pandemic has had a significant impact on business production and demand, staff presence, logistics, and distribution.
The index has not been in positive territory since September, and December's figure was lower than the 47.8 reading predicted by Bloomberg analysts.
For its part, the non-manufacturing PMI -- which includes the services and construction sectors -- also contracted further this month, to 41.6 points from 46.7 in November.


Oil Prices Slide Nearly 3% as U.S.-Iran Talks Ease Geopolitical Tensions
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom
Asian Currencies Strengthen as Indian Rupee and Australian Dollar Rally
Saks Global to End Saks on Amazon Partnership Amid Bankruptcy Restructuring
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate
South Korea Inflation Hits Five-Month Low as CPI Reaches Central Bank Target
Dollar Holds Firm as Strong U.S. Data, Fed Expectations and Global Central Bank Moves Shape Markets
IMF Forecasts Global Inflation Decline as Growth Remains Resilient
Gold and Asian Stocks Rebound as Market Volatility Eases and Global Sentiment Improves
U.S. and Rwanda Sign $228 Million Health Partnership to Boost Self-Reliance
Trump Backs Review of U.S. Childhood Vaccine Schedule After Hepatitis B Policy Change
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 



